Biohaven Pharmaceutical Holding Company Ltd (BHVN.N)
Get access to over 18 million research reports from over 1,700 sources.
For several years, Reuters.com has provided analyst research reports for downloading. In an effort to streamline our website, analyst research will now be available from our dedicated page for Thomson Reuters On Demand, and the Reuters service will discontinue as of September 30, 2016.
Thomson Reuters On Demand provides over 18 million research reports from 1,700 sources.
Moreover, Thomson Reuters On Demand offers fast and cost-effective solutions that would allow you to retrieve information on:
- private equity
- third-party document and information retrieval
- and much, much more…
Click here to request a report and the team of expert analysts will get back to you shortly, to ensure you get the report you need.
|65||Independent Chairman of the Board|
|46||2015||Chief Executive Officer, Director|
|53||2016||Chief Financial Officer|
|55||2017||Chief Scientific Officer|
|51||2014||Vice President - Clinical Operations|
- Biohaven plunges as investors pit migraine data against Allergan's drug
- Biohaven tumbles as migraine drug efficacy fails to impress investors
- BRIEF-Biohaven Says Achieved Both Co-Primary Regulatory Endpoints In Two Pivotal Phase 3 Trials Of Rimegepant
- BRIEF-Biohaven restructures license agreement with Bristol-Myers Squibb to reduce royalties payable on its migraine product candidates
- BRIEF-Biohaven Pharmaceutical Q4 Loss Per Share $0.75